Data from an investigator-initiated study showed GI Dynamics' EndoBarrier device demonstrated reductions in HbA1c levels and insulin usage without complications upon reimplantation for treatment of patients with obesity and type 2 diabetes. After the first explant, HbA1C levels fell from a baseline of 9.1% to 6.7% and insulin usage from 60iU to 19iU; with the second explant, HbA1C dropped from 7.8% to 7.1% and insulin usage from 33iU to 20iU.
Data show positive results for GI Dynamics' EndoBarrier device
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.